Ignite Creation Date:
2024-05-05 @ 11:29 PM
Last Modification Date:
2024-10-26 @ 10:34 AM
Study NCT ID:
NCT01341652
Status:
COMPLETED
Last Update Posted:
2021-01-20
First Post:
2011-03-24
Brief Title:
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
Sponsor:
University of Wisconsin Madison
Organization:
University of Wisconsin Madison
Study Overview
Official Title:
Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase pTVG-HP Versus GM-CSF Adjuvant in Patients With Non-Metastatic Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators are trying to find new methods to treat prostate cancer The approach the investigators are taking is to try to enhance patients own immune response against the cancer In this study the investigators will be testing the effectiveness of a vaccine that may be able to help the body fight prostate cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Protocol Version 1072015 | OTHER | UW Madison | None |
| 2013-1679 | OTHER | None | None |
| NCI-2011-00965 | REGISTRY | None | None |
| A534260 | OTHER | None | None |
| SMPHMEDICINEMEDICINEH | OTHER | None | None |